Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB

Key Points

• Hsbc Holdings PLC bought 216,949 AnaptysBio shares in the second quarter, valued at approximately $14.9 million and representing about 0.73% of the company.
• Other institutions also increased exposure, including JPMorgan Chase, which expanded its position by 1,631.6%, while AQR Capital, Creative Planning, Russell Investments and Arrowstreet Capital added shares.
• AnaptysBio opened at $57.29, below its $80 consensus analyst price target. The stock has a “Moderate Buy” consensus rating from analysts, though its price-to-earnings ratio remains negative as a clinical-stage biotechnology company.

Hsbc Holdings PLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 216,949 shares of the biotechnology company's stock, valued at approximately $14,928,000. Hsbc Holdings PLC owned about 0.73% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ANAB. AQR Capital Management LLC raised its holdings in shares of AnaptysBio by 153.3% during the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company's stock valued at $558,000 after buying an additional 18,165 shares in the last quarter. Creative Planning grew its position in AnaptysBio by 26.9% during the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company's stock valued at $374,000 after acquiring an additional 3,571 shares during the last quarter. JPMorgan Chase & Co. grew its position in AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company's stock valued at $5,497,000 after acquiring an additional 233,325 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of AnaptysBio during the second quarter worth approximately $528,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of AnaptysBio during the second quarter worth approximately $3,348,000.

AnaptysBio Price Performance

ANAB opened at $57.29 on Friday. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The business has a 50 day simple moving average of $58.57 and a two-hundred day simple moving average of $59.07. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -53.05 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANAB shares. Leerink Partners set a $90.00 price objective on shares of AnaptysBio in a research note on Friday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of AnaptysBio in a research report on Monday. Barclays boosted their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 13th. Piper Sandler cut their price target on shares of AnaptysBio from $95.00 to $93.00 and set an "overweight" rating for the company in a research report on Monday, May 4th. Finally, Zacks Research cut AnaptysBio from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.00.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source